180 Life Sciences Stock Debt To Equity
| ATNF Stock | USD 1.07 0.01 0.93% |
180 Life Sciences fundamentals help investors to digest information that contributes to 180 Life's financial success or failures. It also enables traders to predict the movement of 180 Stock. The fundamental analysis module provides a way to measure 180 Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to 180 Life stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | (9.49) | (9.02) |
180 | Debt To Equity |
180 Life Sciences Company Debt To Equity Analysis
180 Life's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current 180 Life Debt To Equity | 0.02 % |
Most of 180 Life's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, 180 Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
180 Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for 180 Life is extremely important. It helps to project a fair market value of 180 Stock properly, considering its historical fundamentals such as Debt To Equity. Since 180 Life's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of 180 Life's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of 180 Life's interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
180 Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, 180 Life Sciences has a Debt To Equity of 0.021%. This is 99.96% lower than that of the Biotechnology sector and 99.89% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.96% higher than that of the company.
180 Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses 180 Life's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of 180 Life could also be used in its relative valuation, which is a method of valuing 180 Life by comparing valuation metrics of similar companies.180 Life is currently under evaluation in debt to equity category among its peers.
180 Fundamentals
| Return On Equity | -1.74 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 6.46 M | ||||
| Shares Outstanding | 3.18 M | ||||
| Shares Owned By Insiders | 18.13 % | ||||
| Shares Owned By Institutions | 21.32 % | ||||
| Number Of Shares Shorted | 25.91 K | ||||
| Price To Earning | 0.63 X | ||||
| Price To Book | 0.91 X | ||||
| EBITDA | (22.13 M) | ||||
| Net Income | (19.94 M) | ||||
| Cash And Equivalents | 1.63 M | ||||
| Cash Per Share | 0.04 X | ||||
| Total Debt | 1.05 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 0.67 X | ||||
| Book Value Per Share | 3.64 X | ||||
| Cash Flow From Operations | (10.92 M) | ||||
| Short Ratio | 0.53 X | ||||
| Earnings Per Share | 7.98 X | ||||
| Target Price | 80.0 | ||||
| Beta | 0.22 | ||||
| Market Capitalization | 3.4 M | ||||
| Total Asset | 5.26 M | ||||
| Retained Earnings | (127.34 M) | ||||
| Working Capital | (1.42 M) | ||||
| Net Asset | 5.26 M |
About 180 Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze 180 Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 180 Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 180 Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether 180 Life Sciences is a strong investment it is important to analyze 180 Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 180 Life's future performance. For an informed investment choice regarding 180 Stock, refer to the following important reports:Check out 180 Life Piotroski F Score and 180 Life Altman Z Score analysis. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 180 Life. If investors know 180 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 180 Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of 180 Life Sciences is measured differently than its book value, which is the value of 180 that is recorded on the company's balance sheet. Investors also form their own opinion of 180 Life's value that differs from its market value or its book value, called intrinsic value, which is 180 Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 180 Life's market value can be influenced by many factors that don't directly affect 180 Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 180 Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if 180 Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 180 Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.